Swiss Biotech Report 2015
Swiss Biotech Report 2015 Impressum Steering committee Domenico Alexakis, Swiss Biotech Association, Zürich Seraina Benz, SIX Swiss Exchange AG, Zürich Oreste Ghisalba, CTI, Bern Jan Lucht, scienceindustries, Zürich Liv Minder, Switzerland Global Enterprise, Zürich Heinz Müller, Swiss Federal Institute of Intellectual Property, Bern Swiss National Science Foundation, Bern Andrea von Bartenwerffer, SIX Swiss Exchange AG, Zürich Jürg Zürcher, Ernst & Young AG, Basel Further partners Daniel Gygax, biotechnet, Muttenz Concept, layout and design sherif ademi | kommunikationsdesign, Schlieren Scan the QR code to download the Swiss Biotech Report 2015. www.swissbiotechreport.ch Publicly traded Swiss biotech companies 3500 in CHF million 3061 2918 2012 3000 2843 2013 2014 2500 2064 1955 Source: Annual Reports, 2000 1852 website information and EY 1500 1000 728 691 678 525 500 374 233 0 –500 Revenues R&D expenses Profits/losses Liquidity Privately held Swiss biotech companies 2500 in CHF million 2012 2000 2013 1799 1826 1824 2014 1500 Source: EY 1000 848 725 673 650 606 602 500 –68 –63 –98 0 Revenues R&D expenses Profits/losses Liquidity –500 Cover Picture: Picture courtesy of Jürg Zürcher © View from Schynige Platte on “Ussri Sägissa” and “Winteregg”. 31 Table of contents Editorial 4 International relationships – Made in Switzerland 5 International cooperation a prerequisite to research 7 Switzerland 2i – innovation and internationalism 8 Short outline of CTI’s national and international activities 9 Patent literature reflects international focus of Swiss biotech 11 Global network and local production drive success 13 Switzerland: strategic business location for life sciences 14 Gearing up for growth: Molecular Partners powers Swiss biotechs’ rise 15 Year in review 19 Swiss biotech at a glance 28 Facts & figures 29 3 Editorial Switzerland’s success has been built on a combination of inter- nationalism and ‘Swissness’.
[Show full text]